CDK7 and diffuse large B-cell lymphoma: These findings suggest for the first time that inhibiting transcription with SNS-032 targeting CDK7/9 is toxic to DLBCL cells and indicates that CDK7/9 is feasible as a therapeutic target of DLBCL.